Roche Defends Accutane Against New Evidence In NJ Retrial

Law360, New York (March 7, 2014, 8:57 PM EST) -- Hoffman-LaRoche Inc. on Friday urged a New Jersey jury to reject claims its drug Accutane causes inflammatory bowel disease, summating a case that was buttressed by new scientific evidence following an appellate reversal of a $10 million verdict awarded to the plaintiff in 2008.

Orlando R. Richmond of Butler Snow LLP, an attorney for Roche, told a New Jersey state jury that the evidence it heard in more than a month of testimony does not establish a causal connection between Roche’s Accutane and the ulcerative colitis...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.